Journal
CELL REPORTS
Volume 16, Issue 7, Pages 1820-1828Publisher
CELL PRESS
DOI: 10.1016/j.celrep.2016.07.033
Keywords
-
Categories
Funding
- Medical Research Council New Investigator Award [MR/N000609/1]
- Tenovus Scotland research grant
- Medical Research Council [1418157, MR/N000609/1] Funding Source: researchfish
- MRC [MR/N000609/1] Funding Source: UKRI
Ask authors/readers for more resources
Embryonic stem cells (ESCs) can self-renew or differentiate into any cell type, a phenomenon known as pluripotency. Distinct pluripotent states, termed naive and primed pluripotency, have been described. However, the mechanisms that control naive-primed pluripotent transition are poorly understood. Here, we perform a targeted screen for kinase inhibitors, which modulate the naive-primed pluripotent transition. We find that XMD compounds, which selectively inhibit Erk5 kinase and BET bromodomain family proteins, drive ESCs toward primed pluripotency. Using compound selectivity engineering and CRISPR/Cas9 genome editing, we reveal distinct functions for Erk5 and Brd4 in pluripotency regulation. We show that Erk5 signaling maintains ESCs in the naive state and suppresses progression toward primed pluripotency and neuroectoderm differentiation. Additionally, we identify a specialized role for Erk5 in defining ESC lineage selection, whereby Erk5 inhibits a cardiomyocyte-specific differentiation program. Our data therefore reveal multiple critical functions for Erk5 in controlling ESC identity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available